Survival Outcomes of Neoadjuvant Versus Adjuvant Therapy in Patients with T1c, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Surveillance, Epidemiology, and End Results Population-Based Study

Xuelian Wang,Yuhang Shang,Jiayang Zhang,Jiangwei Liu,Zhengbo Fang,Yansong Liu,Weilun Cheng,Yunqiang Duan,Anbang Hu,Jiarui Zhang,Mingcui Li,Yanling Li,Hanyu Zhang,Zhiyuan Rong,Suborna S. Shakila,Fanjing Kong,Baoliang Guo

Cancer（2024）

Cited 0|Views3

Key words

early-stage breast cancer,human epidermal growth factor receptor 2-positive (HER2+),neoadjuvant therapy,Surveillance, Epidemiology, and End Results (SEER),survival outcomes

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined